H
Loading...
Loading...
CDC PLACES (2023, crude) estimates 14.6% of adults in Newark have diagnosed diabetes — 2.6 points above the U.S. 12% figure. Census population 311,549. New Jersey Medicare wound biologics: Novitas Solutions (JL). Hawk Medical is a national HCT/P 361 and wound-care distributor serving licensed Newark clinics — not a walk-in office.
Written for licensed providers. Reviewed by Joe Bradley, Founder & CEO. Content version 2026-09-18. Hawk Medical ships nationwide — this is not a Newark storefront.
Chronic Wound Treatment That Works in Newark, NJ for clinics & physicians. Effective chronic wound treatme… Compliance support & pricing — contact Hawk Medical.
Adult obesity in Newark is 35.9% (CDC PLACES 2023). That shows up in wound offloading and in joint-preservation volume — not as a slogan. CDC PLACES (2023, crude) estimates 14.6% of adults in Newark have diagnosed diabetes — 2.6 points above the U.S. 12% figure. New Jersey is outside CDC’s core Diabetes Belt list; use the PLACES city rate anyway. Hawk Medical is the distributor for chronic wound treatment, not a walk-in clinic.
National Chronic Wound Treatment That Works notes (how the product actually works)America’s Health Rankings (BRFSS 2024) only publishes state diabetes as a range nationally (Colorado 8.4% to West Virginia 18.4%). For Newark we use CDC PLACES instead of interpolating a fake city rate from that range. CDC PLACES (2023, crude) estimates 14.6% of adults in Newark have diagnosed diabetes — 2.6 points above the U.S. 12% figure.
If you already buy chronic wound treatment elsewhere, use this page as a check: homologous-use language, current Novitas Solutions article IDs, and PLACES 14.6% diabetes as the epidemiologic floor. If that is how you already practice, the catalog will fit.
CDC PLACES (2023, crude prevalence) estimates 14.6% of adults — 2.6 points above the U.S. 12% figure. Obesity is 35.9%; arthritis is 19.9%. That is place-level BRFSS modeling, not a clinic census and not a Newark trial.
New Jersey is in CMS MAC JL, administered by Novitas Solutions. CTP and skin-substitute coverage is written at the MAC level. Confirm the current LCD/article before you set utilization — we help practices map product to those rules; we do not override them.
New Jersey is JL. A sister clinic in another state may be a different contractor with different CTP articles. Do not assume one utilization policy ports. We map both if you operate across MACs.
Regulatory lane, storage, and JL coding. Amniotic products used as 361 HCT/Ps are not “better gauze.” Match wound stage and coverage article before you convert the cart.
If you operate in New Jersey and another MAC state, say it on the first call. JL will not port 1:1. We would rather split utilization than watch a sister clinic copy Newark tickets into the wrong jurisdiction.
Contact us to learn how Hawk Medical supports practices in Newark, NJ.
Hawk Medical is a national distributor. Joe Bradley’s clinic uses the same product classes. What is local for Newark is JL geography and published epidemiology — not a street address.
CDC PLACES 2023 crude rate for Newark — 2.6 points above the U.S. 12% figure. Planning input, not an outcomes claim.
New Jersey Part B wound biologics follow this contractor (siblings: DC, DE, MD, PA). We train to the articles. We do not write coverage.
PLACES crude adult arthritis in Newark. Useful for joint-program math; still needs a diagnosis and privileging.
No Newark storefront. Joe Bradley is an active practice owner. chronic wound treatment stays in its regulatory lane — not “FDA-approved stem cell therapy.”
Experience the difference of working with a distributor who understands your practice because we operate one ourselves.